182 related articles for article (PubMed ID: 28623849)
1. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Thakkar N; Guptill JT; Aleš K; Jacobus D; Jacobus L; Peloquin C; Cohen-Wolkowiez M; Gonzalez D;
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):625-634. PubMed ID: 28623849
[TBL] [Abstract][Full Text] [Related]
2. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.
Raja SM; Sanders DB; Juel VC; Harati Y; Smith AG; Pascuzzi R; Richman DP; Wu A; Aleš KL; Jacobus LR; Jacobus DP; Guptill JT;
Muscle Nerve; 2019 Sep; 60(3):292-298. PubMed ID: 31269226
[TBL] [Abstract][Full Text] [Related]
3. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders DB; Juel VC; Harati Y; Smith AG; Peltier AC; Marburger T; Lou JS; Pascuzzi RM; Richman DP; Xie T; Demmel V; Jacobus LR; Aleš KL; Jacobus DP;
Muscle Nerve; 2018 Apr; 57(4):561-568. PubMed ID: 29280483
[TBL] [Abstract][Full Text] [Related]
4. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Diaminopyridine, an orphan drug, in the symptomatic treatment of Lambert-Eaton myasthenic syndrome.
Molgó J; Guglielmi JM
Pflugers Arch; 1996; 431(6 Suppl 2):R295-6. PubMed ID: 8739381
[TBL] [Abstract][Full Text] [Related]
6. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
7. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
8. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
9. [Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine].
Yachachi Monfort A; Cortés Pastor F; de la Rubia Nieto A; Sánchez Garre MJ
Farm Hosp; 2007; 31(4):254-6. PubMed ID: 18052623
[No Abstract] [Full Text] [Related]
10. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
11. Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Kim DS; Claussen GC; Oh SJ
Muscle Nerve; 1998 Aug; 21(8):1107-8. PubMed ID: 9655139
[No Abstract] [Full Text] [Related]
12. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine.
Chan KY; Chang RS; Lau VW; Chan ML; Lai T
Ann Palliat Med; 2016 Oct; 5(4):311-314. PubMed ID: 27506750
[TBL] [Abstract][Full Text] [Related]
13. Effect of 3,4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J; Mills KR
Muscle Nerve; 1998 Sep; 21(9):1196-8. PubMed ID: 9703446
[TBL] [Abstract][Full Text] [Related]
14. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
15. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
[TBL] [Abstract][Full Text] [Related]
16. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
Lee MK; Sunwoo IN; Kim SM
J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
[TBL] [Abstract][Full Text] [Related]
17. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
Mantegazza R
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
[No Abstract] [Full Text] [Related]
18. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine.
Sadeh M; River Y; Argov Z
Muscle Nerve; 1997 Jun; 20(6):735-9. PubMed ID: 9149081
[TBL] [Abstract][Full Text] [Related]
19. Wide spectrum of symptomatic treatment in Lambert-Eaton myasthenic syndrome.
Oh SJ; Kim DS; Kwon KH; Tseng A; Mussell H; Claussen GC
Ann N Y Acad Sci; 1998 May; 841():827-31. PubMed ID: 9668337
[No Abstract] [Full Text] [Related]
20. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]